Literature DB >> 35944151

When Effects Cannot be Estimated: Redefining Estimands to Understand the Effects of Naloxone Access Laws.

Kara E Rudolph1, Catherine Gimbrone1, Ellicott C Matthay2, Iván Díaz3, Corey S Davis4, Katherine Keyes1, Magdalena Cerdá5.   

Abstract

Violations of the positivity assumption (also called the common support condition) challenge health policy research and can result in significant bias, large variance, and invalid inference. We define positivity in the single- and multiple-timepoint (i.e., longitudinal) health policy evaluation setting, and discuss real-world threats to positivity. We show empirical evidence of the practical positivity violations that can result when attempting to estimate the effects of health policies (in this case, Naloxone Access Laws). In such scenarios, an alternative is to estimate the effect of a shift in law enactment (e.g., the effect if enactment had been delayed by some number of years). Such an effect corresponds to what is called a modified treatment policy, and dramatically weakens the required positivity assumption, thereby offering a means to estimate policy effects even in scenarios with serious positivity problems. We apply the approach to define and estimate the longitudinal effects of Naloxone Access Laws on opioid overdose rates.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35944151      PMCID: PMC9373236          DOI: 10.1097/EDE.0000000000001502

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.860


  37 in total

1.  Doubly robust estimation in missing data and causal inference models.

Authors:  Heejung Bang; James M Robins
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

2.  A rose by any other name still needs to be identified (with plausible assumptions).

Authors:  Tarik Benmarhnia; Kara E Rudolph
Journal:  Int J Epidemiol       Date:  2019-12-01       Impact factor: 7.196

3.  A new approach to hierarchical data analysis: Targeted maximum likelihood estimation for the causal effect of a cluster-level exposure.

Authors:  Laura B Balzer; Wenjing Zheng; Mark J van der Laan; Maya L Petersen
Journal:  Stat Methods Med Res       Date:  2018-06-19       Impact factor: 3.021

4.  Drug Overdose Deaths in the United States, 1999-2019.

Authors:  Holly Hedegaard; Arialdi M Miniño; Margaret Warner
Journal:  NCHS Data Brief       Date:  2020-12

5.  Drug Overdose Deaths in the United States, 1999-2015.

Authors:  Holly Hedegaard; Margaret Warner; Arialdi M Minino
Journal:  NCHS Data Brief       Date:  2017-02

6.  On causal inference in the presence of interference.

Authors:  Eric J Tchetgen Tchetgen; Tyler J VanderWeele
Journal:  Stat Methods Med Res       Date:  2010-11-10       Impact factor: 3.021

7.  Prescription Drug Monitoring Programs and Opioid Overdoses: Exploring Sources of Heterogeneity.

Authors:  Alvaro Castillo-Carniglia; William R Ponicki; Andrew Gaidus; Paul J Gruenewald; Brandon D L Marshall; David S Fink; Silvia S Martins; Ariadne Rivera-Aguirre; Garen J Wintemute; Magdalena Cerdá
Journal:  Epidemiology       Date:  2019-03       Impact factor: 4.822

8.  Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.

Authors:  Yuhua Bao; Yijun Pan; Aryn Taylor; Sharmini Radakrishnan; Feijun Luo; Harold Alan Pincus; Bruce R Schackman
Journal:  Health Aff (Millwood)       Date:  2016-06-01       Impact factor: 6.301

Review 9.  Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States.

Authors:  Rosanna Smart; Bryce Pardo; Corey S Davis
Journal:  Addiction       Date:  2020-07-08       Impact factor: 6.526

10.  What to Do When Everything Happens at Once: Analytic Approaches to Estimate the Health Effects of Co-Occurring Social Policies.

Authors:  Ellicott C Matthay; Laura M Gottlieb; David Rehkopf; May Lynn Tan; David Vlahov; M Maria Glymour
Journal:  Epidemiol Rev       Date:  2022-01-14       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.